A5050881417- Pancreatic and Hepatic Oncology Research
- Gallbladder and Bile Duct Disorders
- Pediatric Hepatobiliary Diseases and Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Esophageal and GI Pathology
- Pancreatitis Pathology and Treatment
- Cancer Genomics and Diagnostics
- Biliary and Gastrointestinal Fistulas
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Gastrointestinal disorders and treatments
- Cancer Diagnosis and Treatment
- Colorectal Cancer Surgical Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Medical Imaging and Pathology Studies
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Treatments and Studies
- Liver Disease Diagnosis and Treatment
- Tracheal and airway disorders
- Nutrition and Health in Aging
- Cancer Immunotherapy and Biomarkers
- Organ Transplantation Techniques and Outcomes
- Foreign Body Medical Cases
- Liver Disease and Transplantation
Japanese Foundation For Cancer Research
2016-2025
Hokkaido University
1973-2024
The Cancer Institute Hospital
1984-2023
Cancer Institute (WIA)
2016-2023
Mitsubishi Tanabe Pharma Corporation
2023
Sapporo Hokuyu Hospital
2021-2022
The University of Tokyo
2008-2019
National Institute for Land and Infrastructure Management
2016-2018
Ministry of Land, Infrastructure, Transport and Tourism
2016
Toho University Medical Center Sakura Hospital
2015
A method for the determination of free, active insulin in sera insulin-treated diabetics is described. This involved radioimmunoassay after extraction free with polyethylene glycol. Recovery tests cold showed 73 per cent recovery and no bound insulin. The fasting levels were slightly lower patients than normal persons; exceptions some complications expected to cause resistance at peripheral tissue level. Free did not correlate total levels, antibody titers, requirements or conditions...
The renin-angiotensin system (RAS) is thought to have a role in carcinogenesis, and RAS inhibition may prevent tumour growth.We retrospectively investigated the impact of angiotensin I-converting enzyme inhibitors (ACEIs) II type-1 receptor blockers (ARBs) 155 patients with pancreatic cancer receiving gemcitabine monotherapy. Patients were divided into three groups: ACEI/ARB group (27 an ACEI or ARB for hypertension (HT)), non-ACEI/ARB HT (25 antihypertensive drugs other than ACEIs ARBs),...
Abstract Background Biliary tract cancer (BTC) has a poor prognosis and lacks standardized second-line therapy. Vascular endothelial growth factor (VEGF), fibroblast receptor (FGFR) 4, platelet-derived (PDGFR) are highly expressed in BTC. Therefore, lenvatinib (a known inhibitor of VEGF receptors 1–3, FGFRs 1–4, PDGFR-α) was evaluated for treatment Methods In this single-arm, multicenter, open-label, phase 2 study, patients with BTC received 24 mg orally once daily 28-day cycles. The primary...
471 Background: CCA represents ~3% of all gastrointestinal malignancies globally; it is particularly prevalent in Asian countries. Additionally, FGFR2 gene fusions occur ~13% intrahepatic cases. Tasurgratinib (E7090) an orally available selective inhibitor FGFR 1–3; the recommended dose 140 mg per day dose-escalation part a first-in-human phase 1 study. In this pivotal 2 study, regimen was evaluated patients (pts) with fusion-positive CCA. Methods: Japanese and Chinese pts surgically...
This randomised phase II trial compared gemcitabine alone vs and S-1 combination therapy in advanced pancreatic cancer. Patients were randomly assigned to 4-week treatment with (1000, mg m−2 by 30-min infusion on days 1, 8, 15) or 1 15 40 orally twice daily 1–15). The primary end point was progression-free survival (PFS). Between July 2006 February 2009, 106 patients enrolled. PFS arm significantly longer than (5.4 3.6 months), a hazard ratio of 0.64 (P=0.036). Overall (OS) for that...
Covered metallic stents (CMSs) were developed to overcome tumor ingrowth in uncovered (UMSs) for malignant biliary obstruction, but superiority of CMSs over UMSs is still controversial due the high migration rate CMS. Therefore, we conducted this retrospective analysis clarify risk factors stent migration, including mechanical properties CMSs.Patients with unresectable pancreatic cancer, receiving CMS distal obstruction five tertiary care centers, retrospectively studied. Univariate and...
This study investigates the use of serum DUPAN-2 in predicting PC progression CA19-9 nonsecretors.Although we previously reported that >500U/ mL is a poor prognostic factor and an indication for enhanced neoadjuvant treatment, there not biomarker surrogate equivalently predicts prognosis nonsecretors.We evaluated consecutive patients who underwent pancreatectomy from 2005 to 2019. All were categorized as either nonsecretor or secretor (CA19-9 ≤ >2.0U/mL).Of 984 resected patients, 94 (9.6%)...
To evaluate the efficacy and safety of nanvuranlat [an L-type amino acid transporter 1 inhibitor] monotherapy as a later-line treatment in advanced, metastatic, refractory biliary tract cancers.
Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas have been reported to be associated with extrapancreatic malignancies, but there no prospective studies evaluating incidence cancers in patients IPMNs. In this study, frequency IPMNs developing during follow-up was examined.642 were prospectively followed up for 4.8 years on average. They underwent clinical examination at least twice a year. The observed malignancies compared expected age- and gender-matched general Japanese...
Endoscopic bilateral self-expandable metallic stent (SEMS) placement in a stent-in-stent method for malignant hilar biliary obstruction is technically challenging. Technical difficulties the initial and reinterventions occlusion are disadvantages inherent to this method. We previously reported feasibility of Niti-S large cell D-type stents (LCD). This multicenter prospective consecutive study evaluated efficacy SEMS using modified LCD with uniform cells, slimmer delivery system high radial...